Back to Search Results
Study Complete
Sponsor ID
20030194

Evaluating ABX-EGF Extended Therapy in Subjects with MetastaticColorectal Cancer

Sponsor ID
20030194
Clinicaltrials.gov ID
NCT00113776
EUCTIS ID
N/A
EudraCT ID
N/A
Contact Us

Study Details

The purpose of this study is to examine the safety of ABX-EGF

administered as monotherapy in subjects with metastatic colorectal cancer

who were previously randomized to best supportive care (BSC) in protocol

20020408 and subsequently determined to have progressive disease.

Additional Study Details

Phase
Phase 2
Product
panitumumab
Type
Interventional
Masking
None (Open Label)
Enrollment
N/A
Additional Study Details

Protocol Summary

Primary Outcome Measures
Not Available
Secondary Outcome Measures
Not Available

Study Documents

Study Synopsis
Available Language(s): English
Download Document(s)

Locations

No locations found.
Study Info
Age
18+ years
Condition
  • Colorectal Cancer
    • Sex
    All
    Trial Dates
    Mar 2004 - N/A
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    - Subject previously randomized to BSC in protocol 20020408 and subsequently determined to have progressive disease - ECOG performance status of 0, 1 or 2 - Adequate hematologic, renal and hepatic function
    Exclusion Criteria:
    - Myocardial infarction in time interval between completing 20020408 and enrollment in study - History or evidence of interstitial pneumonitis or pulmonary fibrosis - Prior anti-tumor therapies including prior experimental agents or approved anti-tumor small molecules and biologics during the time interval between completing 20020408 protocol and enrollment in this study - Use of systemic chemotherapy or radiotherapy during the time interval between completing 20020408 protocol and enrollment in this study